Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | PNMT | P11086 | 4/20 | 0.34 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31014049 | 0.84 | KDM4E (0.30) | — | |
| SCHEMBL31066342 | 0.82 | HRH3 (0.40) | CYP3A4HTR2CPNMTCD44MAOB | |
| SCHEMBL5777544 | 0.82 | PARP1 (0.33) | CYP3A4HTR2C | |
| SCHEMBL16217182 | 0.82 | CYP3A4 (0.41) | CYP3A4HTR2CPNMTCD44MAOB | |
| SCHEMBL23530014 | 0.79 | CYP3A4 (0.44) | CYP3A4HTR2CPNMTCD44MAOB | |
| SCHEMBL29549874 | 0.79 | CYP3A4 (0.44) | CYP3A4HTR2CPNMTCD44MAOB | |
| SCHEMBL16168344 | 0.78 | HTR2C (0.44) | CYP3A4HTR2CPNMTCD44MAOB | |
| Hydrochloric Acid SCHEMBL2913328 | 0.78 | HTR2C (0.40) | CYP3A4HTR2CPNMTCD44MAOB | |
| Hydrochloric Acid SCHEMBL2912094 | 0.77 | HTR2C (0.43) | CYP3A4HTR2CPNMTCD44MAOB | |
| SCHEMBL16210108 | 0.76 | CYP3A4 (0.41) | CYP3A4HTR2CPNMTCD44MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040132728-A1 | Combinations of atorvastatin and alpha1adrenergic receptor antagonists | PFIZER INC | 2004-07-08 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | CYP3A4 273/4885HTR2C 296/4885PNMT 1504/4885 |
| US-20040132728-A1 | Combinations of atorvastatin and alpha1adrenergic receptor antagonists | ADRA1A, ADRA1D, ADRB1 | CYP3A4 1911/4885HTR2C 791/4885PNMT 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.